Filter Results:
- Full text PDF available (26)
Publication Year
1986
2018
- This year (4)
- Last 5 years (10)
- Last 10 years (21)
Publication Type
Co-author
Journals and Conferences
Learn More
- William Michael Caudle, Julia H. Richardson, +7 authors Gary W. Miller
- The Journal of neuroscience : the official…
- 2007
The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is responsible for packaging dopamine into vesicles for subsequent release and has been suggested to serve a neuroprotective role in the… (More)
- Amy B. Manning-BoÄŸ, Alison L. McCormack, Jie Li, Vladimir N. Uversky, Anthony L. Fink, Donato A. Di Monte
- The Journal of biological chemistry
- 2002
alpha-Synuclein-containing aggregates represent a feature of a variety of neurodegenerative disorders, including Parkinson's disease (PD). However, mechanisms that promote intraneuronal… (More)
- Jyothi Mallajosyula, Deepinder Chhina Rajdeep Singh Chhina Jaspreet Kaur, +6 authors Julie K Andersen
- PloS one
- 2008
Age-related increases in monoamine oxidase B (MAO-B) may contribute to neurodegeneration associated with Parkinson's disease (PD). The MAO-B inhibitor deprenyl, a long-standing antiparkinsonian… (More)
- Xiaoming Hu, Dan Zhang, +11 authors Jau-Shyong Hong
- Journal of immunology
- 2008
Neuronal death is known to trigger reactive microgliosis. However, little is known regarding the manner by which microglia are activated by injured neurons and how microgliosis participates in… (More)
- Eric K. Richfield, Mona J. Thiruchelvam, +5 authors Howard J. Federoff
- Experimental Neurology
- 2002
Human alpha-synuclein (halpha-SYN) is implicated in the Parkinson's disease phenotype (PDP) based on a variety of studies in man, animal models, and in vitro studies. The normal function of… (More)
- Piu Chan, Donato A. Di Monte, Jinhua Luo, L E Delanney, Ian Irwin, James William Langston
- Journal of neurochemistry
- 1994
To study the relationship between energy impairment and the effects of d-methamphetamine (METH) on dopaminergic neurons, ATP and dopamine levels were measured in the brain of C57BL/6 mice treated… (More)
- Maryka Quik, Heather Cox, Neeraja Parameswaran, Kathryn O'Leary, James William Langston, Donato A. Di Monte
- Annals of neurology
- 2007
OBJECTIVE
Levodopa, the gold standard for Parkinson's disease treatment, is associated with debilitating abnormal involuntary movements or dyskinesias, for which few treatments are currently… (More)
- John Goers, Amy B. Manning-BoÄŸ, +5 authors Anthony L. Fink
- Biochemistry
- 2003
The aggregation of alpha-synuclein is believed to play an important role in the pathogenesis of Parkinson's disease as well as other neurodegenerative disorders ("synucleinopathies"). However, the… (More)
- Mona J. Thiruchelvam, Alison McCormack, +4 authors Deborah A. Cory-Slechta
- The European journal of neuroscience
- 2003
While advancing age is the only unequivocally accepted risk factor for idiopathic Parkinson's disease, it has been postulated that exposure to environmental neurotoxicants combined with ageing could… (More)
- Christine Thiffault, James William Langston, Donato A. Di Monte
- Brain Research
- 2000
Because of the potential role of mitochondrial dysfunction in nigrostriatal degeneration in Parkinson's disease, the effects of rotenone (an inhibitor of mitochondrial NADH dehydrogenase and a… (More)